The results showed that SLMP53-1 treatment (50 mg/kg, twice a week during two weeks) modulated the protein levels of typical glycolytic and OXPHOS markers, in p53-expressing, but not in p53-null, tumor tissues. This evidence concerns the gene TP53 and neoplasm.